Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gianluca Furneri
Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
Farmeconomia. Health economics and therapeutic pathways
The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database
Rheumatology and Therapy
Related publications
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Efficacy of Continued Cetuximab for Unresectable Metastatic Colorectal Cancer After Disease Progression During First-Line Cetuximab-Based Chemotherapy: A Retrospective Cohort Study
Oncotarget
Oncology
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Xeloda as First-Line Therapy of Metastatic Colorectal Cancer-Our Experience
Archive of Oncology
Oncology
Hematology
First-Line Treatment of Metastatic Lung Cancer—New Developments
Oncology & Hematology Review (US)
PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With Kras Wild-Type Tumours in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan
JAMA Oncology
Cancer Research
Oncology
Molecular Targeted Treatment of Metastatic Colorectal Cancer: The Cardiovascular Adverse Effects of Bevacizumab and Cetuximab
Medicine and Pharmacy Reports
Medicine
